Profile data is unavailable for this security.
About the company
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
- Revenue in USD (TTM)209.22m
- Net income in USD45.91m
- Incorporated2006
- Employees128.00
- LocationProtagonist Therapeutics Inc7707 Gateway Blvd Ste 140NEWARK 94560-1160United StatesUSA
- Phone+1 (510) 474-0170
- Fax+1 (302) 636-5454
- Websitehttps://www.protagonist-inc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcellx Inc | 35.90m | -217.90m | 3.96bn | 163.00 | -- | 8.98 | -- | 110.34 | -3.92 | -3.92 | 0.6462 | 7.63 | 0.0505 | -- | 9.57 | 220,233.10 | -30.67 | -27.24 | -37.39 | -32.13 | -- | -- | -607.01 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.01bn | 59.00 | -- | 11.64 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.05bn | 437.00 | -- | 3.77 | -- | 2,639.66 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 4.06bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.15bn | 113.00 | -- | 5.86 | -- | 1,910.91 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.25bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 598.70m | -14.06m | 4.49bn | 499.00 | -- | 19.16 | -- | 7.50 | -0.0458 | -0.0458 | 1.94 | 0.7469 | 0.7234 | 0.4175 | 5.65 | 1,199,808.00 | -1.70 | -23.63 | -2.17 | -28.66 | 89.77 | 89.34 | -2.35 | -53.29 | 2.09 | 0.8067 | 0.6298 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.63bn | 196.00 | -- | 6.86 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.69bn | 196.00 | -- | 18.61 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Celcuity Inc | 0.00 | -162.72m | 4.84bn | 87.00 | -- | 38.67 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -210.69m | 4.84bn | 218.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -23.87 | -- | -25.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -36.72 | -- | -- | -- |
| Protagonist Therapeutics Inc | 209.22m | 45.91m | 5.09bn | 128.00 | 129.07 | 7.88 | 107.59 | 24.35 | 0.6313 | 0.6313 | 3.26 | 10.34 | 0.3205 | -- | 52.34 | 1,660,452.00 | 7.03 | -7.11 | 7.55 | -7.93 | -- | -- | 21.94 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.24bn | 362.00 | -- | 5.31 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Alkermes Plc | 1.52bn | 338.06m | 5.48bn | 1.80k | 16.43 | 3.16 | 14.87 | 3.60 | 2.02 | 2.02 | 9.06 | 10.50 | 0.6784 | 1.11 | 4.20 | 845,187.80 | 15.08 | 6.99 | 19.01 | 9.14 | 86.04 | 83.31 | 22.22 | 10.68 | 3.27 | -- | 0.00 | 0.00 | -6.36 | 5.87 | -28.32 | -- | -18.11 | -- |
| Immunitybio Inc | 82.56m | -348.62m | 5.86bn | 673.00 | -- | -- | -- | 70.93 | -0.4079 | -0.4079 | 0.0965 | -0.5323 | 0.1869 | 0.0857 | 4.56 | 121,404.40 | -78.93 | -109.27 | -91.33 | -251.12 | 90.40 | -- | -422.38 | -11,599.51 | 5.65 | -2.20 | 2.77 | -- | 2,270.58 | 46.27 | 29.09 | -- | 9.95 | -- |
Data as of Feb 13 2026. Currency figures normalised to Protagonist Therapeutics Inc's reporting currency: US Dollar USD
63.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 8.32m | 13.31% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 6.22m | 9.95% |
| RTW Investments LPas of 30 Sep 2025 | 5.76m | 9.21% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.94m | 7.90% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.20m | 5.12% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 3.17m | 5.07% |
| UBS Securities LLCas of 31 Dec 2025 | 2.76m | 4.42% |
| BVF Partners LPas of 30 Sep 2025 | 2.56m | 4.10% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.45m | 2.32% |
| Woodline Partners LPas of 30 Sep 2025 | 1.44m | 2.30% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
